# Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

> **NCT06395844** · PHASE1,PHASE2 · RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** METR-NK cell(Metabolic Remodeling Nature Killer Cells)

## Key facts

- **NCT ID:** NCT06395844
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06395844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06395844, "Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06395844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*